These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32142738)

  • 21. pH sensitive liposomes delivering tariquidar and doxorubicin to overcome multidrug resistance of resistant ovarian cancer cells.
    Xia Y; Fang M; Dong J; Xu C; Liao Z; Ning P; Zeng Q
    Colloids Surf B Biointerfaces; 2018 Oct; 170():514-520. PubMed ID: 29960952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance.
    Wang J; Sun J; Chen Q; Gao Y; Li L; Li H; Leng D; Wang Y; Sun Y; Jing Y; Wang S; He Z
    Biomaterials; 2012 Oct; 33(28):6877-88. PubMed ID: 22770799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nitric Oxide Stimulated Programmable Drug Release of Nanosystem for Multidrug Resistance Cancer Therapy.
    Wang L; Chang Y; Feng Y; Li X; Cheng Y; Jian H; Ma X; Zheng R; Wu X; Xu K; Zhang H
    Nano Lett; 2019 Oct; 19(10):6800-6811. PubMed ID: 31466437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells.
    Chakravarty G; Mathur A; Mallade P; Gerlach S; Willis J; Datta A; Srivastav S; Abdel-Mageed AB; Mondal D
    Biochimie; 2016 May; 124():53-64. PubMed ID: 26844637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line.
    Shaik MS; Chatterjee A; Singh M
    J Pharm Pharmacol; 2004 Jul; 56(7):899-907. PubMed ID: 15233869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells.
    Wang J; Goh B; Lu W; Zhang Q; Chang A; Liu XY; Tan TM; Lee H
    Biol Pharm Bull; 2005 May; 28(5):822-8. PubMed ID: 15863886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-delivery of a RanGTP inhibitory peptide and doxorubicin using dual-loaded liposomal carriers to combat chemotherapeutic resistance in breast cancer cells.
    Haggag Y; Abu Ras B; El-Tanani Y; Tambuwala MM; McCarron P; Isreb M; El-Tanani M
    Expert Opin Drug Deliv; 2020 Nov; 17(11):1655-1669. PubMed ID: 32841584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel nanostructured enoxaparin sodium-PLGA hybrid carriers overcome tumor multidrug resistance of doxorubicin hydrochloride.
    Wang J; Wu L; Kou L; Xu M; Sun J; Wang Y; Fu Q; Zhang P; He Z
    Int J Pharm; 2016 Nov; 513(1-2):218-226. PubMed ID: 27628785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug.
    Ling L; Ismail M; Du Y; Yao C; Li X
    Int J Pharm; 2019 Apr; 560():246-260. PubMed ID: 30769133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversion of Multidrug Resistance by Co-Encapsulation of Doxorubicin and Metformin in Poly(lactide-co-glycolide)-d-α-tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles.
    Shafiei-Irannejad V; Samadi N; Salehi R; Yousefi B; Rahimi M; Akbarzadeh A; Zarghami N
    Pharm Res; 2018 Apr; 35(6):119. PubMed ID: 29671072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
    Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
    Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
    Zhang ZL; Jiang QC; Wang SR
    Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
    Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ
    J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Co-delivery of DOX and PDTC by pH-sensitive nanoparticles to overcome multidrug resistance in breast cancer.
    Cheng X; Li D; Sun M; He L; Zheng Y; Wang X; Tang R
    Colloids Surf B Biointerfaces; 2019 Sep; 181():185-197. PubMed ID: 31132609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Indomethacin-grafted and pH-sensitive dextran micelles for overcoming inflammation-mediated multidrug resistance in breast cancer.
    Zeng X; Cheng X; Zheng Y; Yan G; Wang X; Wang J; Tang R
    Carbohydr Polym; 2020 Jun; 237():116139. PubMed ID: 32241443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram.
    Duan X; Xiao J; Yin Q; Zhang Z; Yu H; Mao S; Li Y
    ACS Nano; 2013 Jul; 7(7):5858-69. PubMed ID: 23734880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual-Functional Peptide Driven Liposome Codelivery System for Efficient Treatment of Doxorubicin-Resistant Breast Cancer.
    Ahmed KS; Liu S; Mao J; Zhang J; Qiu L
    Drug Des Devel Ther; 2021; 15():3223-3239. PubMed ID: 34349500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quercetin and doxorubicin co-encapsulated biotin receptor-targeting nanoparticles for minimizing drug resistance in breast cancer.
    Lv L; Liu C; Chen C; Yu X; Chen G; Shi Y; Qin F; Ou J; Qiu K; Li G
    Oncotarget; 2016 May; 7(22):32184-99. PubMed ID: 27058756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vitamin E D-alpha-tocopheryl polyethylene glycol 1000 succinate-conjugated liposomal docetaxel reverses multidrug resistance in breast cancer cells.
    Li N; Fu T; Fei W; Han T; Gu X; Hou Y; Liu Y; Yang J
    J Pharm Pharmacol; 2019 Aug; 71(8):1243-1254. PubMed ID: 31215039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential therapy with redox-responsive glucolipid nanocarrier separately delivering siRNA and doxorubicin to overcome multidrug resistance.
    Meng T; Lu B; Shao S; Yuan M; Liu X; Yuan H; Huang X; Hu F
    Int J Pharm; 2017 Dec; 534(1-2):368-377. PubMed ID: 29051118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.